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Introduction
The emergence in all regions of the world of strains of pathogenic bacteria and fungi with resistance to commonly used antibiotics constitutes a serious threat to public health and has necessitated a search for novel types of antimicrobial agent to which the microorganisms have not been exposed 1 . Although effective new types of antibiotics against multidrug-resistant Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) have been introduced or are in clinical trials, the situation regarding new treatment options for infections produced by multidrug-resistant Gram-negative pathogens such as Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Stenotrophomonas maltophilia is less encouraging 2 . Peptides with potent antibacterial and antifungal activity play an important role in the system of innate immunity that predates adaptive immunity and constitutes the first-line defense against invading pathogens for a wide range of vertebrate and invertebrate species 3 . Antiinfective compounds based upon such peptides are being increasingly considered as potential therapeutic agents 4 . Although development of resistance to antimicrobial peptides has been demonstrated experimentally in vitro 5 , it occurs at rates that are orders of magnitude lower than those observed for conventional antibiotics. Major obstacles to the development of peptide-based anti-infective drugs, particularly if they are to be administered systemically, are their toxicities and their short half-lives in the circulation 6 . However, peptides applied to infected skin or skin lesions in the form of sprays or ointments can penetrate into the stratum corneum to kill microorganisms so that future therapeutic applications are more likely to involve topical rather than systemic administration.
Skin secretions from many species of Anura (frogs and toads) contain a wide range of compounds with biological activity, often in very high concentration, that have excited interest because of their potential for drug development 7 . Among these substances are host-defense peptides with broad-spectrum antibacterial and antifungal activities and the ability to permeabilize mammalian cells 8 . Over 20 years have passed since the discovery of the magainins in the skin of African clawed frog, Xenopuslaevis. These peptides, identified independently by Michael Zasloff at the National Institutes of Health, Bethesda, U.S.A. 9 and by the group of Dudley H. Williams at the University of Cambridge, U.K. 10 , were the first amphibian peptides with antimicrobial activity to be fully characterized. Since that time several hundred such peptides have been isolated from the skin secretions of many other frogs belonging to different families. However, despite showing potent activity against strains of antibiotic-resistant bacteria and against certain pathogenic fungi and protozoa, the potential of these peptides as therapeutic agents has not been realized. No anti-infective peptide based upon their structures has yet been adopted in clinical practice. This review will examine possible clinical application of several well characterized antimicrobial peptides that have been isolated from frog skin. Those peptides with therapeutic potential that have been discovered at the United Arab Emirates University are shown in Table 1 .
Molecular Properties of Frog Skin Antimicrobial Peptides
Frog skin antimicrobial peptides vary in size from as small as 8up to 48 amino acid residues 11 and a comparison of their amino acid sequences reveals the lack of any conserved domains that are associated with biological activity. However, with few exceptions, these peptides are cationic, generally with a molecular charge between +2 and +6 at pH 7 due to the presence of multiple lysine residues, and contain at least 50% hydrophobic amino acids of which leucine and isoleucine are usually the most abundant. Circular dichroism and NMR studies have shown that they generally lack stable secondary structure in aqueous solutions but have the propensity to form an amphipathic α-helix in the environment of a phospholipid vesicle or in a membranemimetic solvent such as 50% trifluoroethanolwater 12 . There is no single mechanism by which peptides produce cell death but their action generally does not involve binding to a specific receptor rather a non-specific interaction with the bacterial cell membrane that results in permeabilization and ultimate disintegration 13 . Consequently, they are usually active against microorganisms resistant to currently licensed antibiotics due to their markedly different mode of action.
The frog skin antimicrobial peptides may be grouped together in peptide families on the basis of limited similarities in amino acid sequence. Skin secretions from a single species frequently contain several members of a particular family that are presumed to have arisen from multiple duplications of an ancestral gene. The molecular heterogeneity of the peptides within a particular family is considerable with a peptide from one species rarely being found with an identical amino acid sequence in another, even when those species are quite closely related phylogenetically 14 . The variation in primary structure is reflected in a wide variability in antimicrobial potencies and specificities for different microorganisms and it has been suggested that this multi-plicity may provide a broader spectrum of defense against the range of pathogenic microorganisms encountered in the environment 15 .
Peptides Active Against Methicillin-Resistant
Staphylococcus aureus (MRSA) Methicillin resistance first appeared among nosocomial isolates of S. aureus in 1961 and since that time MRSA has emerged to become a major phenotype in hospitals worldwide with a high rate of mortality 16 . MRSA produces an alternative transpeptidase with low affinity for β-lactam antibiotics which results in not only methicillin resistance but in vivo non-susceptibility to almost all β-lactam antibiotics. More recently, new strains of MRSA have emerged in the community causing infections in young, otherwise healthy people 17 . In addition to β-lactam resistance, MRSA strains may exhibit multidrug resistance, including non-susceptibility to several other classes of antibiotics such as quinolones, macrolides and sulphonamides 18 .
Temporin-DRa, isolated from skin secretions of the California red-legged frog Ranadraytonii 19 , shows high growth-inhibitory potency against clinical isolates of MRSA (Minimum Inhibitory Concentration, MIC = 8 µM) and has the advantages of ease of synthesis and high solubility 20 . Its therapeutic potency is limited by moderately high hemolytic activity (LC50 = 65 µM). However, the analog containing the amino acid substitution Val 7 → Lys retains activity against MRSA (MIC in the range 8 -16 µM) but has very low hemolytic activity (LC50 > 300 µM) 20 . As well as increasing cationicity, the substitution Val 7 → Lys decreases amphipathicity by increasing the polar angle θ (the angle subtended by the positively charged residues) from 100° to 140° thereby delocalizing the positive charge over a greater surface area of the molecule 21 .
Brevinin-2-related peptide (B2RP-ERa) was first isolated from skin secretions of the South-East Asian Green Paddy frog Hylaranaerythraea (formerly Ranaerythraea) 22 . The C-terminally α-amidated peptide shows limited structural similarity to brevinin-2 peptides isolated from other Asian species but lacks the C-terminal cyclic heptapeptide domain (Cys-Lys-Xaa4-Cys). B2RP-ERa was active against clinical strains of MRSA belonging to different epidemic clonal lineages with MIC values in the range 25 to 50 µM. In time-kill kinetic assays, B2RP at a concentration of 2 x MIC was bacteriostatic but at a concentration of 4×MIC the peptide was bactericidal with 99.9% of bacteria killed within 24 hours. The hemolytic activity of the peptide was relatively low (LC50 = 280 µM) (unpublished data).
Peptides Active against Extended-Spectrum β-Lactamase (ESBL) Producing Bacteria
Bacteria which possess extended-spectrum β-lactamases (ESBLs) have the capacity to hydrolyse a broad spectrum of beta-lactam antibiotics, including third generation cephalosporins 23 . Originally observed in Escherichia coli and Klebsiella spp, ESBL production has now been documented in other Gram-negative bacilli including Proteus mirabilis, Citrobacterfreundii, Shigellasonnei, Serratiamarcescens, Acinetobacter spp. and Salmonella spp. 24 . The epidemiology of ESBL producing Enterobacter iaceae is changing with the incidence of community-acquired infections progressively increasing 25 . Treatment of patients with bacterial infections caused by such multiresistant bacteria is challenging as antibiotic options are becoming increasingly limited.
Ascaphin-8 is a cationic α-helical peptide isolated from skin secretions of the tailed frog Ascaphustruei that shows broad-spectrum antibacterial activity but is also moderately toxic to human erythrocytes (LC50=55µM) 26 . All ESBL-producing clinical isolates of Escherichia coli (MIC=1.5-6 µM) and Klebsiella pneumoniae (MIC=12.5-25µM) strains tested were susceptible to ascaphin-8, as well as a group of miscellaneous ESBL-producing strains (Citrobacter, Salmonella, Serratia, Shigella spp.) (MIC≤ 25µM) 27 . Analogs of ascaphin-8 in in which the amino acids at positions 10, 14, or 18 were replaced by lysine retained potent anti-bacterial activity while showing very low hemolytic activity (LC50 >500 µM). Unexpectedly, ESBL-producing strains of Proteus mirabilis were susceptible toascaphin-8 (MIC=12.5 -25 µM) although non-ESBL isolates of this organism were resistant to these peptides (MIC>100 µM).
Pseudin-2, a 24 amino-acid-residue antimicrobial peptide first isolated from the skin of the South American paradoxical frog Pseudisparadoxa 28 , also shows potential for treatment of infections caused by ESBL-producing Gramnegative bacteria, particularly E. coli. The naturally occurring peptide has weak hemolytic activity but also relatively low potency against microorganisms. However, analogs of the peptide with increased cationicity and decreased α-helicity showed improved therapeutic properties 29 . [D-Lys 3 , D-Lys 10 , D-Lys 14 ] pseudin-2 showed potent activity against Gram-negative bacteria (MIC against several antibioticresistant strains of E. coli = 5 µM) but very low hemolytic activity (HC50 > 500 µM) and cytolytic activity against L929 fibroblasts (LC50 = 215µM). Time-kill studies demonstrated that the analog at a concentration of 1 x MIC was bactericidal against E. coli (99.9% cell death after 96 min) but was bacteriostatic against S. aureus.
Kassinatuerin-1, a 21-amino-acid C-terminally α-amidated peptide isolated from the skin of the African frog Kassinasenegalensis, shows broad-spectrum antimicrobial activity but its therapeutic potential is limited by its relatively high cytolytic activity against mammalian cells 30 . Analogs containing L-lysine substitutions at Gly 7 , Ser 18 , and Asp 19 displayed increased antimicrobial potency but also increased hemolytic activities. In contrast, the analog with Dlysine at positions 7, 18 and 19 was active against a range of strongly antibiotic-resistant strains of E. coli (MIC = 6 -12.5 µM) but showed no detectable hemolytic activity at 400 µM. However, the reduction in α-helicity produced by the D-amino acid substitutions resulted in analogs with reduced potencies against Gram-positive bacteria and against the opportunistic yeast pathogen Candidaalbicans 31 .
Peptides Active Against Multidrug-Resistant Acinetobacter baumannii (MDRAB)
There has been a dramatic increase in the number of hospital acquired infections caused by the opportunistic Gram-negative pathogen A. baumannii during the past decade 32 . These are typically encountered in immunocompromised and critically ill patients in intensivecare and burns units. However, reports of increasing incidence of community-acquired infections 33 and infections of military personnel with war wounds 34 mean that A. baumannii represents a serious threat to public health. Among strains causing nosocomial outbreaks, resistance to fluoroquinolones, aminoglycosides, sulphonamides, third-generation cephalosporins and even carbapenems are common. Treatments with alternative drugs such as polymyxins, particularly colistin (polymyxin E), and the glycylcycline, tigecycline are far from optimal due to concerns with nephrotoxicity regarding colistin and the bacteriostatic nature of tigecycline 35 . Furthermore, increasing use of these antibiotics is already leading to the emergence of resistant strains. The antibiotic resistance of A. baumannii arises from a combination of different possible mechanisms: production of hydrolysing enzymes, activation of multi-drug efflux pumps, modification of the drug target, and poor penetration due to loss of porins 36 . These mechanisms are unlikely to reduce the efficacy of antimicrobial peptides.
Alyteserin-1c, isolated from skin secretions of the midwife toad Alytesobstetricans 37 displays potent activity against clinical isolates of MDRAB (MIC = 5 -10 µM; Minimum Bactericidal Concentration, MBC = 5 -10 µM) while displaying low hemolytic activity against human erythrocytes (LD50 = 220 µM) 38 4 ]alyteserin-1c containing a palmitate group coupled either to the α-amino group at the N-terminus was synthesized. The peptide retained antimicrobial activity against MDRAB but showed dramatically increased hemolytic activity (> 40-fold).
Brevinin-2 related peptide (B2RP), isolated from skin secretions of the mink frog Lithobatesseptentrionalis 39 , represents a second peptide with therapeutic potential for treatment of MDRAB infections. B2RP potently inhibited the growth of nosocomial isolates of multidrug-resistant A. baumannii (MIC = 3 -6 µM). B2RP also shows relatively high potency (MIC ≤ 25 µM) against Gram-positive and Gram-negative bacteria and against the opportunistic yeast pathogen C. albicans but its therapeutic potential is limited by moderate hemolytic activity against human erythrocytes (LC50 = 90 µM) 40 . Increasing cationicity of B2RP without changing amphipathicity by the substitution Asp 4 →Lys resulted in increased potency against MDRAB isolates (MIC = 1.5 -3 µM) and a 4-fold increase in potency against E. coli (MIC = 6 µM) and 2-fold increases in potency against S. aureus (MIC = 12.5 µM) and Candida albicans (MIC = 6 µM) without changing significantly hemolytic activity against human erythrocytes (LC50 = 95 µM). The analogs [Lys 4 , Lys 18 ] B2RP and [Lys 4 , Ala 16 Lys 18 ] B2RP showed reduced potency against S. aureus but they retained activity against A. baumannii (MIC = 3 -6 µM) and had very low hemolytic activity (LC50 > 400 µM).
There is a growing body of evidence demonstrating that histones, and peptide fragments derived from histones, may play a role in the defence against microorganisms in addition to their "classical" role in chromatin formation 41 . Buforin 2, comprising a fragment of histone H2A, was isolated from an extract of stomach tissue of the toad Bufobufogargarizans and its formation may involve the action of pepsin upon the cytoplasmic unacetylated histone H2A that is released into the gastric lumen 42 . The peptide does not produce cell lysis but penetrates the membrane and inhibits cellular functions by binding strongly to DNA and RNA 43 . Buforin 2 was particularly effective (MIC range 0.25 -16 µg/ml) against multidrug-resistant strains of A. baumanni 44 and S. maltophilia 45 isolated from immunocompromised hospital patients.
Peptides
Active Against Azole-Resistant Candida spp. The widespread use of azoles has led to the rapid development of multidrug resistance in C. albicans and other Candida species, which poses a major problem for antifungal therapy 46 . Patients in ICU, undergoing abdominal surgery 47 ,orprolonged immunosuppressive therapy for transplants or treatment of malignancy 48 , and patients with indwelling devices 49 are particularly at risk for nosocomial Candida infections.
Brevinin-1BYa is a cationic α-helical peptide containing an intramolecular disulphide bridge that was first isolated from skin secretions of the foothill yellow-legged frog Ranaboylii 50 . As well as showing growth inhibitory activity against a range of reference strains of Gram-positive and Gram-negative bacteria and against clinical isolates of MRSA (MIC = 2.5 µM), the peptide was active against reference strains and clinical isolates of the opportunistic yeast pathogens C. albicans, C. tropicalis, C. krusei and C. parapsilosis (MIC≤ 10µM) 51 . However, the therapeutic potential of the peptide, especially for systemic applications, is restricted by its high hemolytic activity against human erythrocytes (LD50 = 10 µM). Replacement of the cysteine residues in brevinin-1BYa by serine produced an acyclic analogue with eight-fold reduced hemolytic activity that retained high potency against strains of MRSA (MIC = 5 µM) but activities against yeast species were reduced (MIC in the range 10 -40 µM). More recently, a cyclic analog of brevinin-1BYa was prepared in which the intramolecular disulphide bridge in the peptide was replaced by a metabolically stable, nonreducible dicarba bond. The resulting compound showed increased antifungal activity (MIC against C. albicans = 3 µM) but this advantage was offset by increased hemolytic activity (LD50 = 4µM) 52 .
Peptides Active Against Antibiotic-Resistant

Pseudomonas aeruginosa
The opportunistic Gram-negative bacillus Pseudomonas aeruginosa is characterized by its intrinsic resistance to several antibiotics and for its abilities to colonize diverse habitats and cause serious disease in vulnerable populations 53 . The bacterium is found in low concentrations amongst the intestinal and skin flora of healthy humans but in compromised hosts, such as immunosuppressed patients and those with neutropenia, burns, cancer, diabetes mellitus and chronic lung disease, it is responsible for life-threatening infections 54 . In particular, P. aeruginosa is the major pathogen in the lungs of patients with cystic fibrosis where its survival is enhanced by conversion to biofilm-growing mucoid (alginate-producing) strains 55 . Hospitals represent a reservoir of drug-resistant strains so that nosocomial infections of the respiratory and urinary tracts constitute a growing problem 56 .
Brevinin-2PRa, isolated from an extract of the skin of the Hokkaido frog, Ranapirica, displayed high potency (MIC values between 6 and 12 µM) against a range of clinical isolates of P. aeruginosa with varying degrees of antibiotic resistance and activity was unaffected by NaCl concentrations up to 200mM 57 . The peptide was also active against reference strains of other Gram-negative (E. coli, Enterobacter cloacae, and K. pneumoniae) and Gram-positive (S. aureus, S. epidermidis) bacteria but displayed moderate hemolytic activity (LC = 55 µM).
Peptides of the esculentin-1 family, first identified in the hybrid frog Ranaesculenta, comprise 46 amino acid residues but the amidated N-terminal fragment, esculentin-1-(1-18)-peptide (GIFSKLAGKKLKNLLISG.NH2) has the same antimicrobial activity as the intact peptide 58 . The fragment displayed potent and rapid bactericidal activity (MIC = 1 µM) against multidrug-resistant strains of P. aeruginosa and activity was partially preserved in the presence of 40% serum 59 .
Peptides Active Against Polymicrobial Infections of Foot Ulcers in Diabetic Patients
Foot infections are the most common cause of hospitalisations and amputations in diabetic patients. They occur after skin ulcers or trauma in patients with peripheral neuropathy, sometimes together with vascular disease and are generally polymicrobial. Although the naturally occurring magainins from African clawed frogs of the genus Xenopushave only moderate potency against microorganisms, the analogpexiganan acetate (MSI-78) showed distinct promise as a topical anti-infective agent for the treatment of infected foot ulcers in diabetic patients. Pexiganan represents a more cationic analogue of magainin-2 that contains an additional five lysine residues and an α-amidated C-terminus 60 . Pexiganan exhibited broad-spectrum antibacterial activity when tested against 3,109 clinical isolates of Gram-positive and Gram-negative aerobic and anaerobic bacteria 61 . The MIC value at which 90% of isolates were inhibited (MIC90) was less than or equal to 32 µg/ml for all microorganisms tested except Proteus mirabilis and Serratiamarcescens. For 92% of the isolates tested, MBCs were the same or within a twofold difference of the MIC, consistent with a bactericidal action. A related study involving 2515 bacterial isolates from infected foot ulcers from diabetic patients produced similar results with MIC90 values for pexiganan of 16 µg/ml or less for Gram-positive aerobes, Gram-negative aerobes and facultative anaerobes 62 . It was concluded that pexiganan exhibits properties in vitro which make it an attractive candidate for development as a topical antimicrobial agent 63 . In phase III multicentre, randomised, double-blind trials in diabetic patients with infected foot ulcers, topical application of pexiganan acetate achieved clinical cure or improvement in about 90% of patients and the agent was well tolerated. However, the US Food and Drug Administration did not approve marketing of this peptide on the grounds that efficacy had not been sufficiently demonstrated.
Future Clinical Applications of Frog Skin Antimicrobial Peptides
The failure of pexiganan to become established in clinical practice resulted in a substantial decline in interest in frog skin antimicrobial peptides by the pharmaceutical industry. For progress in the field to continue, new clinical applications need to be found. Acne vulgaris is a disease of the pilosebaceous unit with both bacterial and inflammatory components. The Gram-positive anaerobic bacillus Propioni bacterium acnes is found in normal human cutaneous flora and colonisation and proliferation by this organism plays a major role in the development of an acne lesion 64 . Bacterial colonisation is preceded by hyperproliferation of keratinocytes and increased sebum secretion in a hair follicle together with stimulation of release of cytokines, such as interleukin (IL)-6 and IL-8 by follicular keratinocytes and IL-8 and IL-12 by macrophages 65 . Antibiotic resistance in P. acnes following prolonged monotherapy has been documented 66 . The acyclic brevinin-1 peptide RV-23 from R. draytonii (originally described as a melittinrelated peptide) 19 showed potent growthinhibitory activity (MIC < 10 µM) against isolates of P. acnes from blood cultures 67 . Previous studies have shown that cationic antimicrobial peptides, as well as possessing microbicidal actions, will inhibit the release of proinflammatory cytokines and so may reduce the inflammatory response that follows bacterial skin colonisation 68, 69 . Thus, further studies are warranted to determine whether frog skin peptides such as RV-23 may exercise a dual beneficial role in acne treatment by manifesting a bactericidal action on P. acnes and an anti-inflammatory effect on host cells.
In a similar manner, the formation of microbial biofilms in the oral cavity can initiate a cascade of inflammatory responses that lead to the destruction of gingival tissues and ultimately tooth loss. There is an extensive literature relating to antimicrobial peptides and proteins in saliva and gingival crevicular fluid that provide protection against pathogenic microorganisms 70 . Magainin and selected analogs show potent and rapid bactericidal activity against a range of anaerobic oral pathogens such as Porphyromonas gingivalis, Fusobacterium nucleatum, and Prevotella spp. 71 . More recently, caerulein precursor fragment CPF-AM1 from the African clawed frog Xenopusamieti 72 has shown particularly high potency (MIC < 2.5 µM) against the cariogenic microorganisms Streptococcus mutans and Lactobacillus acidophilus (F. Lundy and J.M. Conlon, unpublished data). Consequently, a role of such frog skin peptides in the prevention and treatment of periodontal disease is a possibility.
